Metsigletic

Metformin Hydrochloride and Sitagliptin, the active ingredient in Metsigletic, is a Biguanide and DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by improving blood glucose control through reduced hepatic glucose output and enhanced insulin secretion.

GNH USA supplies Metsigletic as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU GMP standards and providing reliable, bulk sourcing for global markets with robust quality assurance and timely delivery.

Metsigletic, a combination of metformin and sitagliptin, is used in the management of type 2 diabetes mellitus, targeting hyperglycemia through complementary mechanisms.

- Type 2 diabetes mellitus: improves fasting and post‑prandial glucose levels, helping achieve target HbA1c. - Inadequate control on metformin monotherapy: provides additional glucose‑lowering effect when metformin alone is insufficient. - Adjunct to diet and exercise: supports glycaemic control as part of comprehensive lifestyle management. - Patients with obesity and type 2 diabetes: assists in weight‑neutral glycaemic control.

Metsigletic may cause adverse reactions; the frequency of events varies among patients.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools, usually transient. - Abdominal discomfort: cramping or pain. - Headache: mild headache. - Upper respiratory tract infection: cold‑like symptoms. - Hypoglycaemia (when combined with insulin or sulfonylureas): low blood sugar episodes.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic disturbance. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reaction: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Persistent vomiting leading to dehydration. - Acute renal failure: sudden loss of kidney function.

Before prescribing Metsigletic, clinicians should consider several safety precautions.

- Renal function assessment: evaluate eGFR and avoid use in severe renal impairment. - Hepatic monitoring: check liver enzymes periodically, especially in patients with liver disease. - Risk of lactic acidosis: discontinue if signs of metabolic acidosis appear. - Pregnancy and lactation: category B; use only if benefits outweigh potential risks. - Concomitant hypoglycaemic agents: adjust dose of sulfonylureas or insulin to prevent hypoglycaemia. - Store at ambient temperature: keep tablets in the original container, protect from moisture and heat.

Metsigletic can interact with other medicines; awareness of major and moderate interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction when combined with metformin. - Phenformin: co‑administration is contraindicated due to high risk of lactic acidosis. - Insulin or sulfonylureas: can cause severe hypoglycaemia if doses are not adjusted.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase sitagliptin plasma levels. - Diuretics (thiazides): can affect renal clearance of metformin. - Corticosteroids: may raise blood glucose, requiring dose adjustments. - Oral contraceptives: may slightly increase metformin concentrations. - ACE inhibitors: monitor renal function and potassium levels.